WO1998016266A1 - Implantable acrylamide copolymer hydrogel for therapeutic uses - Google Patents

Implantable acrylamide copolymer hydrogel for therapeutic uses Download PDF

Info

Publication number
WO1998016266A1
WO1998016266A1 PCT/CA1997/000766 CA9700766W WO9816266A1 WO 1998016266 A1 WO1998016266 A1 WO 1998016266A1 CA 9700766 W CA9700766 W CA 9700766W WO 9816266 A1 WO9816266 A1 WO 9816266A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
tissue
hydrogel
cells
polymer hydrogel
Prior art date
Application number
PCT/CA1997/000766
Other languages
French (fr)
Inventor
Stéphane Woerly
Original Assignee
Organogel Canada Ltee.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organogel Canada Ltee. filed Critical Organogel Canada Ltee.
Priority to EP97944663A priority Critical patent/EP0929323B1/en
Priority to AT97944663T priority patent/ATE284717T1/en
Priority to BR9706835-7A priority patent/BR9706835A/en
Priority to JP51786898A priority patent/JP3542810B2/en
Priority to IL12489497A priority patent/IL124894A/en
Priority to CA002240721A priority patent/CA2240721C/en
Priority to SK796-98A priority patent/SK79698A3/en
Priority to DE69731959T priority patent/DE69731959T2/en
Priority to AU46126/97A priority patent/AU744666B2/en
Priority to NZ330664A priority patent/NZ330664A/en
Publication of WO1998016266A1 publication Critical patent/WO1998016266A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3878Nerve tissue, brain, spinal cord, nerves, dura mater
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/041Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • This invention relates to a polymer hydrogel. More particularly, the present invention is concerned with a porous, implantable polymer hydrogel for therapeutic uses, for example, which can be used for internal tissue replacement of any portion of soft organs, for wound healing, for tissue regeneration, and for organ repair in general, especially in the developing and adult nervous system, and other like therapies.
  • the invention is especially directed at a polymer hydrogel which, upon implantation becomes a porous matrix which is filled with biological fluids and molecules to form a so-called organoid hydrogel, and becomes progressively integrated into the host by subsequent ingrowth of tissue and blood vessels.
  • the invention also relates to a method of introducing living tissue cells, precursor cells or genetically modified cells within such polymer hydrogel to produce biohybrid materials which are useful for three-dimensional cell cultures or for tissue reconstruction.
  • the invention also relates to a method for the production of the polymer hydrogel according to the invention, and to biohybrid materials produced by the method mentioned above.
  • the present invention relates to a method for treating damaged parts of the central nervous system, especially the spinal cord and optic nerve, or of peripheral nerves, or other tissues by implantation therein of the polymer hydrogel or the biohydrid materials according to the invention.
  • Organ transplantation is presently the only alternative to alleviate organ failures and to restore or improve the function and performance of organs.
  • some of the drawbacks of organ-transplant therapies are the potential for donor-to-recipients disease transmission, the shortage and the limited availability of donor organs, and possible immunological cross- reactions.
  • spinal cord transplantation is neither clinically nor biologically feasible and consequently there is no treatment available for SCI patients, while in the United States alone there are 250,000 chronically paralyzed patients with an increase of 10,000 new SCI patients each year.
  • implantation, transplantation or injection of cells into the body to replace or restore missing cells or part of tissue organs cannot properly achieve formation of new tissues because of the lack of a supporting extracellular matrix as a necessary tissue framework for tissue expansion and organization into an integrated structure in contact with the host organ.
  • the cells need to be placed in a physiologically-equivalent environment that facilitate diffusion of nutrients, oxygen, humoral and cellular components in order to maintain high cell viability and growth potential after implantation.
  • Porous hydrogels of the present invention are deformable porous polymer matrices saturated with interstitial fluid or water, and thus provide the necessary tissue framework and hydrated space through which the cells can proliferate and assemble into supracellular tissue architectures in a correct histological structure to obtain a functional neotissue.
  • donor tissue grafts either syngenic autograft or homograft, allograft or xenograft
  • spinal cord such as fetal neural tissue
  • a solid graft e.g. Bregman, Dev. Brain Res., 34, 265, 1987; Houle and Reier, J. Comp. Neural., 269, 535, 1988
  • suspension grafts including mixed neural tissue cells e.g. Goldberg and Bernstein, J.
  • peripheral nerve segment including cultured non- neuronal cells (Wrathall et al, Acta Neuropathol, 57, 59, 1982) or with embryonic neural tissue (Horvat et al., Res. Neural. Neurosci., 2, 289, 1991).
  • prosthetic materials which have been disclosed include pure collagen matrices (de la Torre and Goldsmith, Brain Res., Bull., 35, 418, 1994; Marchand and Woerly, Neurosci. 36, 45, 1990; Gelderg, Brain Res.
  • Polymer hydragels have been disclosed as implants in the nervous system (Woerly et al., Biomaterials, 11, 97, 1990; Woerly et al., Biomaterials, 12, 197, 1991; Woerly et al., J. Neural Transpl. Plast. 3, 21, 1992; Woerly et al., Cell Transpl., 2, 229, 1993; Woerly et al., J. Neural Transpl. Plast., 5, 245, 1995).
  • hydragels were prepared by free radical polymerization in water, using ammonium persulfate and sodium metabisulfite or persulfate and ascorbic acid as redox initiators with either hydroxyethyl methacrylate (pHEMA), glycidyl methacrylate pGMA) or N-hydraxypropyl methacrylamide (pHPMA) or a composition including the above monomers with a cross-linking agent which is either ethylene glycol and tetraethylene glycol dimethacrylate or methylene-bis-acrylamide.
  • HEMA hydroxyethyl methacrylate
  • pGMA glycidyl methacrylate
  • pHPMA N-hydraxypropyl methacrylamide
  • a cross-linking agent which is either ethylene glycol and tetraethylene glycol dimethacrylate or methylene-bis-acrylamide.
  • These gels are typically homogeneous and optically transparent with a bimodal porosity including open (accessible pore volume) and closed pores as shown by mercury porosimetry data and scanning electron microscopy; typically the porous structure for these gels is formed of parallel cylindrical capillaries of circular cross-section as shown in FIG. 1 with an average pore diameter of 7 to 13 ⁇ m.
  • the fractional porosity is in the range of 50% to 85% for pHEMA hydragels, 60% to 65% for pGMA hydragels and 70% to 94% for pHPMA hydragels.
  • At least 50% of the porous volume of the hydrogel is occupied by pore from 1.2 to 4 ⁇ m for pHEMA, 6 to 13 ⁇ m for pGMA and 10 to 14 ⁇ m for pHPMA. It was found that their biological activity was dependent upon the introduction or copolymerization of collagen into the cross-linked network. Applicant experimented implantation in the brain which showed that some degree of tissue repair can be achieved according to the degree of tissue ingrowth into the homogeneous gel matrices. This reaction is variable according to the monomer composition and added functional groups. However, homogeneous hydragels frequently induce the formation of fibrous capsule that tend to isolate the implant from the host.
  • Harvey et al., in Brain Res., 671, 119, 1995 discloses a polymer sponge of poly(2-hydraxyethyl methacrylate) that is used as brain implant for tissue regeneration and axon growth. This product is best used with the addition of collagen to the polymer network as tissue bioadhesive and after inclusion of Schwann cells.
  • U.S. Patent No. 4,902,295 describes a process for preparing an artificial tissue from pancreas tissue cells. The process involves the polymerization of matrix precursors, gel precursors and promotors with viable cells in aqueous phase. All polymer precursors as well as promotors are biological compounds susceptible of rapid biodegration into the body and do not have long term stability after implantation.
  • Biotechnol. Bioeng. 1994, 43, 555-562) describe a technique where PC 12 cells are suspended in gels of collagen alone or combined with fibronectin or laminin, and in gels of agarose and collagen. These gels are biodegradable.
  • Mikos, A.G.; Bao, Y.; Cima, L.G.; Ingber, D.E.; Vacanti, J.P.; Langer, R. (“Preparation of Poly(glycolic acid) Bonded Fiber Structures for Cell Attachment and Transplantation", J. Biomed. Mat. Res. 1993, 27 183-189) describe a process to build networks of poly(glycolic acid) with bonded fibers to culture hepatocytes. This polymer is biodegradable and the process to introduce cells into the matrix is different from entrapment.
  • a non-biological prosthetic device such as a non-degradable polymer hydrogel, that acts as space-filling material and as scaffold builders that stimulate tissue regeneration, morphogenesis and remodeling into an integrated structure-to-organ.
  • Still another object of this invention is to provide biohybrid devices which can be used to replace part of tissue of soft organs.
  • Yet still another object of the present invention is to provide a three- dimensional culture system which can be used to culture a variety of cells in vitro for a prolonged period of time.
  • Another object of the invention is to provide support matrices for the attachment of biologically-active molecules to tissue or organs.
  • Another object of the present invention is to provide a component for systems for controlled release of drugs and macro-molecules, especially anti- inflamatory substances such as indomethacin, stimulators of cytokins, such as bacterial lipopolysaccharides, steroids, such as methyl prenisolone and neuroactive factors, such as fibroblast growth factors.
  • anti- inflamatory substances such as indomethacin
  • stimulators of cytokins such as bacterial lipopolysaccharides
  • steroids such as methyl prenisolone
  • neuroactive factors such as fibroblast growth factors.
  • Another object of the present invention is to provide a swellable material with a high swelling capacity in aqueous media that can adsorb significant amounts of biological interest for the purpose of the present invention such as adhesion molecules, such as CAM and LI molecules, or guidance molecules such as semaphorins or netrins dissolved in a suitable solution, so that the said molecules are subsequently adsorbed onto the surface of the network of the polymer matrix.
  • biological interest such as adhesion molecules, such as CAM and LI molecules, or guidance molecules such as semaphorins or netrins dissolved in a suitable solution, so that the said molecules are subsequently adsorbed onto the surface of the network of the polymer matrix.
  • new hydrophilic polymeric hydrogels which are capable of forming porous, soft, highly absorbent polymer matrices which are elastically deformable and possess an equilibrium water content of at least about 80%, preferably at least 96%.
  • polymer mixtures which can be mixed with living cells.
  • the invention relates to a polymer hydrogel for therapeutic use, which is a copolymer of (a) an N-substituted methacrylamide or acrylamide, (b) a cross- linking agent, and (c) a polymerizable material selected from the group consisting of a sugar, a sugar derivative, a tissue adhesion peptide, tissue differentiating molecules proteins such as bone morphogenetic proteins and a polymer conjugate with antibodies against lipid derivatives, which is elastically deformable and possesses an equilibrium water content of at least about 80%, preferably at least 96%.
  • the N-substituted methacrylamide or acrylamide (a) is selected from the group consisting of N-monoalkyl and N,N-dialkyl methacrylamides and acrylamides, the cross-linking agent, (b) comprises acrylamide or precursors thereof and the polymerizable material, (c) is a sugar which is selected from the group consisting of glucosamine, N-acetyl glucosamine and an N-acetyl derivative of neuraminic acid and their polymeric forms such as polysialic acid.
  • the invention also relates to a method for preparing a polymer hydrogel for therapeutic use which comprises (a) dissolving a cross-linking agent in a pore-forming solvent with a free radical polymerization initiator to form a solution, (b) adding an N-substituted methacrylamide or acrylamide to the solution obtained in (a) to form a mixture, and (c) adding a solution of a sugar, a sugar derivative, a tissue adhesion peptide, morphogenetic proteins or derived bioactive peptides, or a polymer conjugate with antibodies against lipid derivatives to the mixture obtained in (b).
  • the method comprises dissolving azo-bisisobutyronitrile and methylene bisacrylamide in the solvent to form a solution, mixing the solution with N-2-(hydraxyprapyl) methacrylamide, adding glucosamine or N-acetylglucosamine or N- acetymeuraminic acid thereto, and removing low molecular weight residual products and initiator traces therefrom.
  • the method also comprises adding living tissue cells or genetically modified cells to the product obtained in (c) and effecting polymerization of the cells within said product.
  • the polymer hydrogel according to the invention comprises cells or genetically modified cells polymerized therewith.
  • the invention relates to a method for treating damaged cerebral tissues or spinal cord injuries which comprises removing the damaged cerebral tissues or spinal cord in a human being or animal and replacing the damaged cerebral tissues or spinal cord with a polymer hydrogel according to the invention.
  • the hydrogel according to the invention is a covalently cross-linked, non-transparent, heterogeneous material, which preferably shows a clear phase separated structure formed of polymer particles of about 1 to 10, preferably 3 to 5 ⁇ m so as to provide an area of relatively coarse porosity (macropores) where the hydrogel is intended to interface with a host tissue and relatively fine porosity (mesopores) where it is intended to interface with ingrowing tissue.
  • a covalently cross-linked, non-transparent, heterogeneous material which preferably shows a clear phase separated structure formed of polymer particles of about 1 to 10, preferably 3 to 5 ⁇ m so as to provide an area of relatively coarse porosity (macropores) where the hydrogel is intended to interface with a host tissue and relatively fine porosity (mesopores) where it is intended to interface with ingrowing tissue.
  • a preferably sponge-like structure with a macroporous structure a fractional porosity of, for example, at least 80 to 90% (volume of mercury intrusion to the total volume of gel); a specific surface area in the range of preferably hundreds of square meter/gram of gel; a median pore diameter (volume), of for example, about 15 to 35 ⁇ m; a porous volume for pores equal to or greater than 10 ⁇ m equal to 100% of the fractional porosity of the hydrogel; a hyperporous character (fractional porosity of the gel at least 50% of the gel volume) from 20 - 30 ⁇ m.
  • the macrostructure and porosity of the hydrogels can be manipulated by controlling the size of the particles and the porous structure which depend on the composition and the properties of the pore-forming solvent used, the polymer volume fraction, the polymer-solvent interaction, the polymerization temperature and the properties of the cross-linking monomer used.
  • Successful biomass accumulation and cell interaction result from such an optimal surface/volume interaction as shown by mercury porosimetry data that result from micro- and mesoporosity of the polymer particles.
  • An important final aspect of the material is its open nature and interconnectedness suitable for biomass cell accumulation and cell/molecular interactions with live tissue. Under scanning electron microscopy, as shown in FIG.
  • these heterogeneous gels typically show a colloidal-type three- dimensional structure with a non-circular pore and the wall of the pore system which is represented by the contiguity of the surface of polymer aggregates, as shown in the drawings.
  • the effective surface area is a function of the porosity of the particle surface.
  • a major advantage of such heterogeneous gels is that the surface area generated by particles is virtually unlimited as the size of the aggregates (1) decreases so that the surface area is inversely proportional to 1.
  • the heterogeneous hydrogels of the present invention show a much larger porous volume and therefore are more effective for cell infiltration and biomass accumulation.
  • the hydrogels according to the invention have mechanical compliance properties matching those of adult and developing neural tissue.
  • the polymer matrices may be formed by simultaneous precipitation or precipitate polymerization and cross-linking copolymerization of an effective amount of each of the following components: (i) N-substituted methacrylamides such as N-monoalkylmethacrylamides or N-substituted acrylamides such as N-monoalkylacrylamides, or N,N-disubstituted acrylamides, such as N,N-dialkylacrylamides; (ii) a cross-linking agent, such as acrylamide or precursors thereof or divinyl compounds, and the like; (iii) a free radical polymerization initiator, such as azobisisobutyronitrile, various peroxides, ascorbic acid, peroxysulfates, substituted azo compounds and the like which are well known to those
  • the alkyl groups preferably have one to two carbon atoms, for example Ci to C2 hydroxyalkyl and amino alkyl radicals.
  • the term N-substituted as used herein includes Cj_8 substituents which may contain OH, an amino group or a combination thereof.
  • the reaction is generally carried out at a temperature of 40° to 60°C in polymerization vessels consisting of sealed ampoules for a period of about 12 hours.
  • FIG. 1 is a microscopical view of a homogeneous gel
  • FIG. 2 is a microscopical view of a homogeneous gel implanted in spinal cirdl
  • FIG. 3 is a microscopical view of a heterogeneous gel of HPMA;
  • FIG 4 is a microscopical view of a gel of Fig. 3 implanted in nervous tissue. MODES FOR CARRYING OUT THE INVENTION
  • N-methacryloyl glucosamine (5% wt), or l-methyl-2-memacryloylamidoethyl-2-acetamido-2-deoxdy- ⁇ -D- glucoside (6.5% wt), or 2-[l-methyl-2-methacryloylamidoethyl) 5-acetamido 3,5-dideoxy-D-glycero- ⁇ -D-galacto-2-nonulopyranosidonic acid (5.2% wt), or methacryloylglycylglycylargynylglycylaspartic acid (1.4% wt) , is dissolved in dimethylsulfoxide and added to the polymerization mixture.
  • the mixture is thoroughly homogenized and loaded in a syringe and injected in ampoules.
  • the reaction mixture is then purged with nitrogen and the ampoules are sealed by flaming.
  • the mixture can be first frozen in a mixture of dry ice and ethanol prior to flaming the ampoule.
  • the sealed ampoules are then immersed in a water bath at 50°C for 24 hours.
  • the low molecular weight residual products such as unreacted monomers, oUgomers that were not included in the network and initiator traces are removed from the hydrogel product prior to its use.
  • the preparation of the polymer gel is preferably done in a biohazard chamber with a filtered air flow.
  • the washing steps are preferably performed using sterile materials and the gels are stored at 4°C in sterile distilled water.
  • cells can be inoculated into the porous strucweture of the polymer hydrogel by micropunctures of the polymer network using a Hamilton seringue containing the said cell suspension. Thye introduction of cells into the said polymer hydrogel can be done either in vitro or in vivo following the adequate dime after implantation of the hydrogel into the target organ area.
  • Cells can be isolated from human brain or muscle tissue or autopsy material
  • EXAMPLE 2 Cell inoculation into PHPMA hydrogel in vitro.
  • Neurons were isolated from cerebral hemispheres of rat embry7os free of meninges and blod vessels in DMEM, and were chopped into small tissue fragments.
  • the tissues were mechanically dissociated with a Pasteur pipette in a centrifuge tube containing DMEM. The supernatant was saved and the settled tissue fragments were further disrupted with a Pasteur pipette that had been fire polished to narrow the tip. After several cycles of cell resuspension/dissociation, the pooled supernatant was centrifuged, and the cells were concentrated to 10 ⁇ cells per 100 ⁇ l of medium. The fraction is kept on ice until used for cell entrapment.
  • cells were introduced into an Hamilton seringue attached to a micromanipulator device and were inoculated with mini9mal pressure damage at the desired concentration into the swollen PHPMA hydrogels under a binocular microscope and in aseptic contions.
  • the cell-containing hydrogels are kept in a minimal volume of culture maxim ⁇ m and incubated at 37°C and 5% CO2 in a humidified atrmosphere.
  • the hybrid device can be transplanted into the brain to facilitate tissue reconstruction and repair.
  • the polymer mixture can be mixed with living cells, thereby combining the physical characteristics of the polymer matrix with hydrogel-type behavior (porosity, stability, guidance surfaces, permeability) and cellular biological factors (e.g., growth factors).
  • hydrogel-type behavior porosity, stability, guidance surfaces, permeability
  • cellular biological factors e.g., growth factors
  • the introduction of the cells into a polymer matrix is achieved by a gel- entrapment process at a temperature below zero, i.e., cryopolymerization, that yields a porous matrix within which cells are immobilized and can achieve reorganization, growth and/or differentiation for subsequent transplantation.
  • the solvent should be an isotonic solution or tissue culture medium of the type which is commonly used in cell and tissue cultures combined with a suitable ciyoprotectant (glycerol/dimethylsufoxide or glycerol or DMSO or polyvinylpyrrolidone or hydroxyethyl starch, carboxymethylcellulose).
  • the process allows to control the final cell densities ranging from a few cells to cell densities approaching the cell density of tissue, approximately 10 ⁇ to 1010 cells/cm ⁇ .
  • the process allows also to vary and control the matrix porosity by varying the rate of cooling and the temperature of the polymerization mixture containing cells (liquid nitrogen or cooled isopentane).
  • the process yields a macroporous spongy structure typical of cryogel with pore size that permit diffusion of nutrients and macromolecules (e.g., growth factors) to and from the cells entrapped within the polymer gel matrix and cell migration, and a pore volume suitable for effective biomass accumulation, expansion (cell division) and organization (cell-to-cell contact) during tissue development and maturation.
  • Astracytes were obtained by incubation of cerebral cortices of two-day old new born rats in a solution containing 0.1% trypsin-EEDTA, 0.001% DNAse in Hepes buffered DMEM for 30 min at 37°C and mechanaical dissociation. Cells were plated onto plastic flasks at 10 ⁇ cells/ 10 ml and maintained at 37°C in DMEM with 10% iFetal Bovin Serum.
  • HBSS Hank's balanced salt solution
  • the pre-polymerization solution consisted of 0.69 g of N-(2-hydroxypropyl)methacrylamide and 0.010 g of methylenebisacrylamide dissolved in 2.3 mL of HBSS containing 20% glycerol, and as initiators, ammonium persulfate (lOOmg/mL HBSS; 4.3 X 10 _ 3 M) wiith N ⁇ N ⁇ N'-tetramethylene diamine diluted in HBSS (1:1 v/v HBSS; 3.3 x 10" 5 M).
  • the pH was adjusted to 7.0 with HC1 0.1N and the pre- polymerization solution was deaerated with nitrogen and precooled to 4°C prior to being used.
  • the gels were removed from the mold, washed with HBSS to remove the cryoprotective agent and unreacted reaction products, and trimmed into circular discs with 0.8 mm diameter.
  • the gel discs were incubated at 37°C and 5% CO 2 m ft humidified atmosphere m DMEM supplemented with 10% FBS and 1% antibiotics (streptomicine- penicilline).
  • the cells are entrapped within the polymeric matrix with a scaffold architecture for organization, large inner surface area, sufficient void spaces for cell expansion and increased permeability.
  • the cell polymer mixture can be kept stored once frozen for subsequent polymerization as described above.
  • the resulting hybrid matrix consists of a solid phase that comprises the porous matrix, the cells and the cell extracellular matrix, and a fluid phase corresponding to the cell culture medium and extracellular fluids.
  • this process is different from the so-called process "cell encapsulation” that uses micro or macroencapsulation techniques and wherein the cells are simply enclosed within a polymer membrane having a spherical shape of variable diameter.
  • tissue(s) intend to include tissue fragments, cell clumps, single cells from embryonic, neonatal or adult origin, genetically modified cells, either primary cells or immortalized cells, immortalized cell lines either from existing tumor cell lines or immortalized precursor cell lines, stem or progenitor cells, growth factor-selected precursor cell lines of any tissues and organs.
  • the process and product of this invention are suitable for preparing a wide variety of artificial tissues or organs for transplantation or of three-dimensional culture systems.
  • a cell suspension in Hank's balanced salt solution (sterile HBSS, pH 7.4) containing 10% to 20% glycerol as cryoprotectant was incubated for 10 minutes at 4°C.
  • the prepolymerization solution consisting of a polymerizable composition as described in EXAMPLE 1 is dissolved in HBSS containing 10% to 20% glycerol.
  • the solution is filtered through a porous glass filter and deaerated in vacuo and precooled in ice. Free radical polymerization is initiated with persulfate ascorbic acid or persulfate teframethylenediamine dissolved in HBSS.
  • the pH of the solution is adjusted to neutral with HC1 IN.
  • the cells are suspended in the polymerization solution at a variable density, preferably 10 ⁇ cells/ml of polymerization mixture.
  • the mixture is thoroughly mixed and loaded in a syringe and injected in ampoules or in a mold made of two glass plates separated by silicone rubber sealant of variable sizes or in ampoules.
  • the mold or ampoules are rapidly frozen by immersion in liquid nitrogen and transferred in a water bath cooled at -10° to -30°C
  • the cryopolymerization reaction is carried out for at least 5 hours, preferably 12 hours.
  • the molds or ampoules are thawed off in a 37°C water bath and the gels are removed, washed with HBSS, and can be sized to appropriate shapes.
  • the gels are transferred to a 5% CO2 incubator with the preferred culture medium containing antibiotics and antifungic drugs. The procedure is done in a flow cabinet and using sterile instruments.
  • TEST 1 The biological tolerance of the polymer hydrogels of the invention was studied by implantation in the transected spinal cord and in brain lesions of rats. Samples for testing were taken up from 1 week up to 10 months after implantation. Biological tolerance was excellent. Macroscopically, the gels integrate to host tissue showing a good stability and in some cases the host organ appears intact. Microscopically, studies have shown that this polymer hydrogel formulation promotes tissue restructuring and axonal regeneration at the site of implantation in the hemi- and transected rat spinal cord and thus achieving up to 100% of tissue continuity restoration (Fig. 4).
  • the cryopolymerisation procedure allowed to generate heterogeneous gels with fixed macroporous structure into which cells are immobilized.
  • Studies using cell labeling technique such as cell labeling or immunocytochemistry, show that the cells are uniformly distributed throughout the polymer network and at different levels within the gels, either as individual isolated cells or arranged in small clusters of a few cells.
  • the cells which survive were positively immunostained throughout three weeks in vitro incubation with antigenic profiles of developing neural tissue cells.
  • astracytes isolated from the neonatal brain of rats can be trapped within hydrophilic hydrogels by cryopolymerization reaction with high levels of retention and the entrapped cells can survive and normally differentiate as they do in monolayer culture conditions: after 10 days in vitro, the viability of entrapped cells is of 90% using cell labeling techniques.
  • the cells are functional as they synthesize laminin and fibronectine within the polymer matrix as they do in monolayer cultures.
  • the polymer hydrogel is intended to be used mainly as a tissue expander and a tissue formation template to replace tissue defect or tissue deficit of soft organs of the body, that result from either a trauma or a surgical manipulation or a congenital malformation, by promoting the formation of a new functionally integrated tissue-to-organ. It is also intended to be used to engineer wound healing, tissue remodelling, tissue regeneration, tissue development of soft organs such as liver, pancreas, skin, muscle. It can also be used in combination with other materials for bone regeneration and repair.
  • polymer hydrogel Another application of the polymer hydrogel is to develop procedures to provide therapy for specific human neurological disorders, and the said polymer hydrogel can be used in two different ways according to the type of disease and the extent of the functional defect.
  • tissue regeneration template or as cell carrier after incorporation of a cell graft.
  • the polymer hydrogel according to the invention is for instance intended to be used to treat damaged or congenital defect of specific areas of the brain and spinal cord in the developing stage or the adult stage (e.g., spinal cord injury).
  • the procedure consists in removing the damaged tissue or scar tissue or any malfunction part of the neural tissue and replacing the cerebral tissue or spinal cord tissue with the polymer hydrogel described above.
  • the polymer hydrogel according to the invention is also useful to reconstitute neuronal circuits that are associated with axonal pathways in the central nervous system in the developing stage or the adult stage.
  • the septo- hippocampala circuits that are involved in the memory function that is impaired for example in Alzheimer disease or the nigro-striatal circuits that are involved in Parkinson disease or part of the striatum in Huntington's disease, or in hormonal/reproduction dysfunctions involving the hypophyso-hypothalamus anatomical system.
  • This is accomplished by surgically removing the defective part of the brain tissue and implanting the gel according to the invention preferably with a neural cell graft in order to induce the formation of new functional axonal circuits.
  • malformations that result in malfunction of the spinal cord circuits can be treated by removing the abnormally formed part of the organ and replacing the defective part by the neurogel according to the invention, preferably with a neuronal cell graft.
  • Another application of the hydrogel according to the invention is the treatment of the optic nerve and peripheral nerves by inducing in the same way axonal regrowth through the polymer hydrogel according to the invention.

Abstract

The hydrogel is a copolymer of an N-substituted methacrylamide or acrylamide, a cross-linking agent and a complex sugar or derivative, a tissue adhesion peptide or a polymer conjugate with antibodies, the polymer being heterogeneous, elastically deformable and having an equilibrium water content of at least about 80 %. It can be used for tissue regeneration and for organ repair, for example, in the developing and adult nervous system.

Description

IMPLANTABLE ACRYLAMIDE COPOLYMER HYDROGEL FOR THERAPEUTIC USES
TECHNICAL FIELD
This invention relates to a polymer hydrogel. More particularly, the present invention is concerned with a porous, implantable polymer hydrogel for therapeutic uses, for example, which can be used for internal tissue replacement of any portion of soft organs, for wound healing, for tissue regeneration, and for organ repair in general, especially in the developing and adult nervous system, and other like therapies. The invention is especially directed at a polymer hydrogel which, upon implantation becomes a porous matrix which is filled with biological fluids and molecules to form a so-called organoid hydrogel, and becomes progressively integrated into the host by subsequent ingrowth of tissue and blood vessels. The invention also relates to a method of introducing living tissue cells, precursor cells or genetically modified cells within such polymer hydrogel to produce biohybrid materials which are useful for three-dimensional cell cultures or for tissue reconstruction. The invention also relates to a method for the production of the polymer hydrogel according to the invention, and to biohybrid materials produced by the method mentioned above. Finally, the present invention relates to a method for treating damaged parts of the central nervous system, especially the spinal cord and optic nerve, or of peripheral nerves, or other tissues by implantation therein of the polymer hydrogel or the biohydrid materials according to the invention. BACKGROUND ART
Organ transplantation is presently the only alternative to alleviate organ failures and to restore or improve the function and performance of organs. However, some of the drawbacks of organ-transplant therapies, are the potential for donor-to-recipients disease transmission, the shortage and the limited availability of donor organs, and possible immunological cross- reactions. Thus, for example, spinal cord transplantation is neither clinically nor biologically feasible and consequently there is no treatment available for SCI patients, while in the United States alone there are 250,000 chronically paralyzed patients with an increase of 10,000 new SCI patients each year.
On the other hand, implantation, transplantation or injection of cells into the body to replace or restore missing cells or part of tissue organs cannot properly achieve formation of new tissues because of the lack of a supporting extracellular matrix as a necessary tissue framework for tissue expansion and organization into an integrated structure in contact with the host organ. In addition, the cells need to be placed in a physiologically-equivalent environment that facilitate diffusion of nutrients, oxygen, humoral and cellular components in order to maintain high cell viability and growth potential after implantation.
Porous hydrogels of the present invention are deformable porous polymer matrices saturated with interstitial fluid or water, and thus provide the necessary tissue framework and hydrated space through which the cells can proliferate and assemble into supracellular tissue architectures in a correct histological structure to obtain a functional neotissue.
Different experimental strategies of intraspinal transplantation have been disclosed in the literature as attempts to restore damages in the spinal cord (animal models), using various implant materials which can be grouped into two broad categories of implants: (1) biological tissues and (2) prosthetic materials.
In category (1) is included the use of donor tissue grafts, either syngenic autograft or homograft, allograft or xenograft, to bridge lesions of spinal cord such as fetal neural tissue, either as (a) a solid graft (e.g. Bregman, Dev. Brain Res., 34, 265, 1987; Houle and Reier, J. Comp. Neural., 269, 535, 1988) or as (b) suspension grafts including mixed neural tissue cells (e.g. Goldberg and Bernstein, J. Neuroscience Res., 19, 34, 1988; Hoovler and Wrathall, Acta Neuropathol., 81, 303, 1991); Schwann cells recombined with cultured sensory neurons (Kuhlengel et al., J. Comp. Neural., 293, 74, 1990); immature astrocytes (e.g., Bernstein and Goldberg, Res. Neural. Neurosci., 2, 261, 1991); precursors of neural tissue cells (Monteros et al., Dev. Neurosci., 14, 98, 1992) and immortalized established cell lines (Zompa et al., Int. J. Dev. Neurosci., 11, 535, 1993); peripheral nerve segment including cultured non- neuronal cells (Wrathall et al, Acta Neuropathol, 57, 59, 1982) or with embryonic neural tissue (Horvat et al., Res. Neural. Neurosci., 2, 289, 1991). For category (2) prosthetic materials which have been disclosed include pure collagen matrices (de la Torre and Goldsmith, Brain Res., Bull., 35, 418, 1994; Marchand and Woerly, Neurosci. 36, 45, 1990; Gelderg, Brain Res. 511, 80, 1990), containing neuroactive agents (Goldsmith and de la Torre, Brain Res., 589, 217, 1992) or including cultured neural grafts (Bernstein and Goldberg, Brain Res. 377, 403, 1986); treated nitrocellulose implants (Schreyer and Jones, Dev. Brain Res., 35, 291, 1987; Houle and Johnson, Neurosci. Lett. 103, 17, 1989); collagen implants (Paino et al., J. Neurocytol., 23, 433, 1991) and polymer guidance channels of poly(acrylonitrile-vinyl chloride) (Xu et al., J. Comp. Neural., 351, 145, 1995) enclosing Schwann cells.
These approaches focus very sharply on the promotion of axonal regeneration using various tissue substrates as sources of new axons or using complex prosthetic substrates to support and guide growing axons, and do not address the clinically relevant issue of spinal cord or brain tissue repair by regeneration of the bulk of the host tissue and remodeling of wound healing, for example, after removing necrotic or scar tissue following injury.
Polymer hydragels have been disclosed as implants in the nervous system (Woerly et al., Biomaterials, 11, 97, 1990; Woerly et al., Biomaterials, 12, 197, 1991; Woerly et al., J. Neural Transpl. Plast. 3, 21, 1992; Woerly et al., Cell Transpl., 2, 229, 1993; Woerly et al., J. Neural Transpl. Plast., 5, 245, 1995). These hydragels were prepared by free radical polymerization in water, using ammonium persulfate and sodium metabisulfite or persulfate and ascorbic acid as redox initiators with either hydroxyethyl methacrylate (pHEMA), glycidyl methacrylate pGMA) or N-hydraxypropyl methacrylamide (pHPMA) or a composition including the above monomers with a cross-linking agent which is either ethylene glycol and tetraethylene glycol dimethacrylate or methylene-bis-acrylamide. These gels are typically homogeneous and optically transparent with a bimodal porosity including open (accessible pore volume) and closed pores as shown by mercury porosimetry data and scanning electron microscopy; typically the porous structure for these gels is formed of parallel cylindrical capillaries of circular cross-section as shown in FIG. 1 with an average pore diameter of 7 to 13 μm. The fractional porosity is in the range of 50% to 85% for pHEMA hydragels, 60% to 65% for pGMA hydragels and 70% to 94% for pHPMA hydragels. At least 50% of the porous volume of the hydrogel is occupied by pore from 1.2 to 4 μm for pHEMA, 6 to 13 μm for pGMA and 10 to 14 μm for pHPMA. It was found that their biological activity was dependent upon the introduction or copolymerization of collagen into the cross-linked network. Applicant experimented implantation in the brain which showed that some degree of tissue repair can be achieved according to the degree of tissue ingrowth into the homogeneous gel matrices. This reaction is variable according to the monomer composition and added functional groups. However, homogeneous hydragels frequently induce the formation of fibrous capsule that tend to isolate the implant from the host. This is due to the mechanical properties of these gels that do not match sufficiently those of the living neural tissue as well as to the small volume fraction of macropores. In the spinal cord, these homogeneous hydragels do not integrate into the host and become rapidly encapsulated by a connective tissue and glial scar without penetration of axons or tissue components, as shown in FIG.2. In addition, there is a physical consideration that limits the surface area that can be generated, an important parameter for successful tissue interaction generated by the cylindrical pores in such homogeneous gels. For a fixed volume of gel, the surface area reaches a limit which is the maximum radius of a single pore occupying the total volume of the gel. On the other hand, increasing the surface area by decreasing the size of pores will lead to a decrease of the total void volume which is incompatible with tissue ingrowth and biomass accumulation.
Harvey et al., in Brain Res., 671, 119, 1995 discloses a polymer sponge of poly(2-hydraxyethyl methacrylate) that is used as brain implant for tissue regeneration and axon growth. This product is best used with the addition of collagen to the polymer network as tissue bioadhesive and after inclusion of Schwann cells.
U.S. Patent No. 4,902,295 describes a process for preparing an artificial tissue from pancreas tissue cells. The process involves the polymerization of matrix precursors, gel precursors and promotors with viable cells in aqueous phase. All polymer precursors as well as promotors are biological compounds susceptible of rapid biodegration into the body and do not have long term stability after implantation.
Bellamkonda, R.; Ranieri, J.P.; Bouche, N.; Aebischer, P. ("Hydragel- Based Three-dimensional Matrix for Neural Cells", J. Biomed. Mat. Res. 1995, 29, 663-671) describe a technique to immobilize neural tissue cells .into agarose and extracellular-equivalent (Matrigel®) gels. These materials are biologic and are biodegradable. Krewson, C.E.; Chung, S.W.; Dai, W.; Saltzman, W.M. ("Cell
Aggregation and Neurite Growth in Gels of Extracellular Matrix Molecules".
Biotechnol. Bioeng. 1994, 43, 555-562) describe a technique where PC 12 cells are suspended in gels of collagen alone or combined with fibronectin or laminin, and in gels of agarose and collagen. These gels are biodegradable.
Cascone, M.G.; Laus, M.; Ricci, D.; Sbarbati del Guerra, R. ("Evaluation of Poly(vinyl alcohol) Hydragels as a Component of Hybrid Artificial Tissues", J. Mat. Sci. Mat. Med. 1995, 6, 71-75) describe a technology using poly (vinyl alcohol) hydragels, physically cross-linked, into which fibroblastic cells are introduced by a one freeze-thawing cycle.
Wald, H.L.; Sarakinos, G.; Lyman, M.D.; Mikos, A.G.; Vacanti, J.P.; Langer, R. ("Cell Seeding in Porous Transplantation", Biomat. 1993, 14, 270- 278) describe a process for enclosing hepatocyte cells into degradable polymer foams of poly(L-lactic acid) by a microinjection technique. This technique does not provide a non-degradable matrix and does not allow uniform cell distribution throughout the polymer matrix.
Mikos, A.G.; Bao, Y.; Cima, L.G.; Ingber, D.E.; Vacanti, J.P.; Langer, R. ("Preparation of Poly(glycolic acid) Bonded Fiber Structures for Cell Attachment and Transplantation", J. Biomed. Mat. Res. 1993, 27 183-189) describe a process to build networks of poly(glycolic acid) with bonded fibers to culture hepatocytes. This polymer is biodegradable and the process to introduce cells into the matrix is different from entrapment.
Puerlacher, W.C.; Mooney, D.; Langer, R.; Upton, J.; Vacanti, J.P.; Vacanti, CA. ("Design of Nasoseptal Cartilage Replacements Synthetized from Biodegradable Polymers and Chondrocytes", Biomat. 1994, 15, 774-778) and Freed, L.E.; Marquis, J.C.; Nohria, A. Emmanual; Mikos, A.G.; Langer, R. ("Neocartilage Formation In Vitro and In Vivo Using Cells Cultured on Synthetic Biodegradable Polymers", J. Biomed. Mat. Res. 1993 27, 11-23). These references describe a process to introduce chondracyte cells into polyglycolic (PGA) or polylactic acid (PLLA) or PGA-PLLA matrices by capillary action. This process yields biodegradable polymer materials while the cells are not uniformly distributed into the polymer and does not allow to control cell density.
Cao, Y.; Vacanti, J.P.; Ma, X.; Paige; K.T.; Upton, J.; Chowanski, Z.; Schloo, B.; Langer, R.; Vacanti, CA. ("Generation of Neo-Tendon Using Synthetic Polymers Seeded with Tenocytes", Transpl. Proc 1994, 26, 3390- 3391) describe a process to seed tenocyte cells into embossed nonwoven mesh of polyglycolic acid.
Mooney, D.J.; Park, S.; Kaufman, P.M.; Sano, K.; McNamara, K.; Vacanti, J.P.; Langer, R. ("Biodegradable Sponge for Hepatocyte Transplantation", J. Biomed. Mat. Res 1995, 29, 959-965) and Takeda, T.; Kim, T.H.; Lee, S.K.; Langer, R.; Vacanti, J.O. ("Hepatocyle Transplantation in Biodegradable Polymer Scaffolds Using the Baltimatian Dog model of Hyperuricosuria", Transpl. Proc. 1995, 27, 635-636) describe a process to absorb hepatocyte cells in sheets of polyglycolic acid polymer felts or into polymer sponges fabricated from polylactic acid and polyvinyl alcohol and from polylactic acid glycolic acid by adsorption and capillary action. This process yields biodegradable polymer materials while the cells are not uniformly distributed into the polymer and does not allow to control cell density.
Woerly, S.; Plant, G.W.; Harvey, A.R. ("Cultured Rat Neuranal and Glial Cells Entrapped within Hydrogel Polymer Matrices: A Potential Tool for Neural Tissue Replacement", Neurosci. Lett. 1996, 205, 197-201) disclose a procedure to entrap neural tissue cells into homogeneous transparent polymer gels of poly[N-(2-hydroxypropyl)-methacrylamide] which can contain collagen as attachment substrate. This procedure involves the addition of a cell suspension to the polymer mixture and the polymerization of the cell-polymer mixture at room temperature or in an incubator maintained at 37°C The resulting gel is optically transparent and cells are randomly dispersed within the cross-linked gel. Immunocytochemical studies indicated that cell viability after 6 days in vitro varied between 0 and 6%. DISCLOSURE OF INVENTION
It is an object of the present invention to prevent the drawbacks of the prior art by using a non-biological prosthetic device such as a non-degradable polymer hydrogel, that acts as space-filling material and as scaffold builders that stimulate tissue regeneration, morphogenesis and remodeling into an integrated structure-to-organ.
It is another object of the present invention to improve the healing of tissue into tissue formation that can be achieved by controlling cell proliferation, cell infiltration and tissue organization within a stable polymer matrix.
It is another object of the present invention to provide for tissue regeneration by means of polymer matrices which would have a great benefit and an important clinical and economical impact for people suffering from spinal cord (SCI) and brain injuries or developmentally defective spinal cord
(spina bifida).
It is another object of the invention to provide polymer matrices for regeneration of the optic nerve and peripheral nerves. It is another object of the present invention to provide a non-degradable synthetic polymer hydrogel matrix with anisotrapic porous structure, effective surface area and good tissue adhesivity and compatibility and which is designed for implantation in soft tissue structure, especially in the nervous system, and which becomes progressively part of the organ. It is another object of the present invention to provide for the therapeutic use of synthetic polymer matrices with controlled pore structure and carrying surface active agents.
It is a primary object of the present invention to provide a polymer matrix which is made of a novel water-insoluble polymer hydrogel that is used in the swollen state as prosthetic devices for tissue regeneration for soft organ repair.
It is another object of the invention to provide a method for the production of a hydrogel product in a mold having the shape of the final prosthetic device. It is yet another object of the present invention to overcome one or more drawbacks of the prior art and to provide a polymer neuroprosthesis which can be implanted in the brain or spinal cord using standard surgical procedures.
It is a further object of this invention to provide a method by which cells or genetically modified cells can be introduced into polymer networks. It is another object of the present invention to provide a polymer mixture that can be mixed with living cells, thereby combining the physical characteristics of a polymer matrix with hydrogel-type behavior (porosity, stability, guidance surfaces, permeability) and with cellular biological factors
(e.g., growth factors). Still another object of this invention is to provide biohybrid devices which can be used to replace part of tissue of soft organs.
Yet still another object of the present invention is to provide a three- dimensional culture system which can be used to culture a variety of cells in vitro for a prolonged period of time.
Another object of the invention is to provide support matrices for the attachment of biologically-active molecules to tissue or organs.
It is another object of the present invention to provide porous hydragels which are deformable porous polymer matrices saturated with interstitial fluid or water, thereby providing the necessary tissue framework and hydrated space through which the cells can proliferate and assemble into supercellular architectures in a correct histological structure to give a functional tissue.
Another object of the present invention is to provide a component for systems for controlled release of drugs and macro-molecules, especially anti- inflamatory substances such as indomethacin, stimulators of cytokins, such as bacterial lipopolysaccharides, steroids, such as methyl prenisolone and neuroactive factors, such as fibroblast growth factors.
It is another object of the invention to provide a material which possesses strong bio-adhesiveness and hemostatic properties suitable for internal soft tissue placement, rapid attachment and at the same time hemostasis.
It is a primary object of the present invention to provide a polymer matrix which has mechanical and chemical stability to sustain long term implantation in the body without degradation that could otherwise damage the new tissue network that has grown into the matrix in replacement of a part of an organ.
It is also another object of the present invention to provide a matrix with the mechanical compliance that allow to cut, to size and to handle the polymer matrix by the operator without changing the internal structure and the mechanical properties of the matrix.
Another object of the present invention is to provide a swellable material with a high swelling capacity in aqueous media that can adsorb significant amounts of biological interest for the purpose of the present invention such as adhesion molecules, such as CAM and LI molecules, or guidance molecules such as semaphorins or netrins dissolved in a suitable solution, so that the said molecules are subsequently adsorbed onto the surface of the network of the polymer matrix.
According to the invention there are provided new hydrophilic polymeric hydrogels which are capable of forming porous, soft, highly absorbent polymer matrices which are elastically deformable and possess an equilibrium water content of at least about 80%, preferably at least 96%.
There is also provided, according to the invention, polymer mixtures which can be mixed with living cells.
The invention relates to a polymer hydrogel for therapeutic use, which is a copolymer of (a) an N-substituted methacrylamide or acrylamide, (b) a cross- linking agent, and (c) a polymerizable material selected from the group consisting of a sugar, a sugar derivative, a tissue adhesion peptide, tissue differentiating molecules proteins such as bone morphogenetic proteins and a polymer conjugate with antibodies against lipid derivatives, which is elastically deformable and possesses an equilibrium water content of at least about 80%, preferably at least 96%.
Preferably, the N-substituted methacrylamide or acrylamide (a) is selected from the group consisting of N-monoalkyl and N,N-dialkyl methacrylamides and acrylamides, the cross-linking agent, (b) comprises acrylamide or precursors thereof and the polymerizable material, (c) is a sugar which is selected from the group consisting of glucosamine, N-acetyl glucosamine and an N-acetyl derivative of neuraminic acid and their polymeric forms such as polysialic acid.
The invention also relates to a method for preparing a polymer hydrogel for therapeutic use which comprises (a) dissolving a cross-linking agent in a pore-forming solvent with a free radical polymerization initiator to form a solution, (b) adding an N-substituted methacrylamide or acrylamide to the solution obtained in (a) to form a mixture, and (c) adding a solution of a sugar, a sugar derivative, a tissue adhesion peptide, morphogenetic proteins or derived bioactive peptides, or a polymer conjugate with antibodies against lipid derivatives to the mixture obtained in (b).
In accordance with a preferred embodiment, the method comprises dissolving azo-bisisobutyronitrile and methylene bisacrylamide in the solvent to form a solution, mixing the solution with N-2-(hydraxyprapyl) methacrylamide, adding glucosamine or N-acetylglucosamine or N- acetymeuraminic acid thereto, and removing low molecular weight residual products and initiator traces therefrom.
In accordance with another embodiment, the method also comprises adding living tissue cells or genetically modified cells to the product obtained in (c) and effecting polymerization of the cells within said product.
According to yet another embodiment, the polymer hydrogel according to the invention comprises cells or genetically modified cells polymerized therewith.
According to yet another embodiment, the invention relates to a method for treating damaged cerebral tissues or spinal cord injuries which comprises removing the damaged cerebral tissues or spinal cord in a human being or animal and replacing the damaged cerebral tissues or spinal cord with a polymer hydrogel according to the invention.
The hydrogel according to the invention is a covalently cross-linked, non-transparent, heterogeneous material, which preferably shows a clear phase separated structure formed of polymer particles of about 1 to 10, preferably 3 to 5 μm so as to provide an area of relatively coarse porosity (macropores) where the hydrogel is intended to interface with a host tissue and relatively fine porosity (mesopores) where it is intended to interface with ingrowing tissue. This results in a preferably sponge-like structure with a macroporous structure; a fractional porosity of, for example, at least 80 to 90% (volume of mercury intrusion to the total volume of gel); a specific surface area in the range of preferably hundreds of square meter/gram of gel; a median pore diameter (volume), of for example, about 15 to 35 μm; a porous volume for pores equal to or greater than 10 μm equal to 100% of the fractional porosity of the hydrogel; a hyperporous character (fractional porosity of the gel at least 50% of the gel volume) from 20 - 30 μm.
The macrostructure and porosity of the hydrogels can be manipulated by controlling the size of the particles and the porous structure which depend on the composition and the properties of the pore-forming solvent used, the polymer volume fraction, the polymer-solvent interaction, the polymerization temperature and the properties of the cross-linking monomer used. Successful biomass accumulation and cell interaction result from such an optimal surface/volume interaction as shown by mercury porosimetry data that result from micro- and mesoporosity of the polymer particles. An important final aspect of the material is its open nature and interconnectedness suitable for biomass cell accumulation and cell/molecular interactions with live tissue. Under scanning electron microscopy, as shown in FIG. 3, these heterogeneous gels typically show a colloidal-type three- dimensional structure with a non-circular pore and the wall of the pore system which is represented by the contiguity of the surface of polymer aggregates, as shown in the drawings. The effective surface area is a function of the porosity of the particle surface. In contrast to homogeneous gels, a major advantage of such heterogeneous gels is that the surface area generated by particles is virtually unlimited as the size of the aggregates (1) decreases so that the surface area is inversely proportional to 1. Also, as compared to homogeneous hydrogels, the heterogeneous hydrogels of the present invention show a much larger porous volume and therefore are more effective for cell infiltration and biomass accumulation. In addition and as compared to homogeneous hydrogels, the hydrogels according to the invention have mechanical compliance properties matching those of adult and developing neural tissue.
These hydrogel matrices have true tissue-specific architectures because cell interaction results in an organized tissue network through the gel structures, so-called organoid hydrogels. The polymer matrices may be formed by simultaneous precipitation or precipitate polymerization and cross-linking copolymerization of an effective amount of each of the following components: (i) N-substituted methacrylamides such as N-monoalkylmethacrylamides or N-substituted acrylamides such as N-monoalkylacrylamides, or N,N-disubstituted acrylamides, such as N,N-dialkylacrylamides; (ii) a cross-linking agent, such as acrylamide or precursors thereof or divinyl compounds, and the like; (iii) a free radical polymerization initiator, such as azobisisobutyronitrile, various peroxides, ascorbic acid, peroxysulfates, substituted azo compounds and the like which are well known to those skilled in the art, in amounts which may vary between 0.01 to 2% by weight with respect to the copolymer or terpolymer; (iv) complex sugars such as glucosamine or N-acetylglucosamine or N-acet lgalactosamine or N-acet meuraminic acid or polysialic acid or other sugar derivatives or tissue adhesion oligopeptides containing sequences, such as Arg-Gly-Asp, Ile-Lys-Val-Ala-Val, Ala His-Ala-Val-Ser-Glu, Tyr-Ile- Gly-Ser-Arg, tissue differentiating molecules-derived oligopeptides (e.g., bone morphogenetic proteins) or polymer conjugate with antibodies against myelin and axon-associated lipids and their derivatives in a solvent preferably acetone/dimethyl sulfoxide, acetone or acetone/ethanol.
The alkyl groups preferably have one to two carbon atoms, for example Ci to C2 hydroxyalkyl and amino alkyl radicals. The term N-substituted as used herein includes Cj_8 substituents which may contain OH, an amino group or a combination thereof.
The reaction is generally carried out at a temperature of 40° to 60°C in polymerization vessels consisting of sealed ampoules for a period of about 12 hours.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 is a microscopical view of a homogeneous gel;
FIG. 2 is a microscopical view of a homogeneous gel implanted in spinal cirdl FIG. 3 is a microscopical view of a heterogeneous gel of HPMA;
FIG 4 is a microscopical view of a gel of Fig. 3 implanted in nervous tissue. MODES FOR CARRYING OUT THE INVENTION
The invention is illustrated by means of the following Example. EXAMPLE 1
ALBN (azobisisobutyronitrile) (1.2% w/w) and methylenebisacrylamide (1 mol%) are dissolved in dry acetone. The solution is mixed with N-2- (hydroxypropyl) methacrylamide to a volume ratio of 30% HPMA with a mixture of acetone/dimethylsulfoxide (93:7 v/v). N-methacryloyl glucosamine (5% wt), or l-methyl-2-memacryloylamidoethyl-2-acetamido-2-deoxdy-β-D- glucoside (6.5% wt), or 2-[l-methyl-2-methacryloylamidoethyl) 5-acetamido 3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonic acid (5.2% wt), or methacryloylglycylglycylargynylglycylaspartic acid (1.4% wt) , is dissolved in dimethylsulfoxide and added to the polymerization mixture. The mixture is thoroughly homogenized and loaded in a syringe and injected in ampoules. The reaction mixture is then purged with nitrogen and the ampoules are sealed by flaming. In order to avoid solvent evaporation, the mixture can be first frozen in a mixture of dry ice and ethanol prior to flaming the ampoule. The sealed ampoules are then immersed in a water bath at 50°C for 24 hours. Preferably, according to the invention, the low molecular weight residual products, such as unreacted monomers, oUgomers that were not included in the network and initiator traces are removed from the hydrogel product prior to its use. This may be achieved by immersing the xerogels in ethanol for 20 hours, then in a mixture of ethanol/water (1: 1 v/v) for 20 hours and in distilled water for one week with frequent water exchanges until the swelling equilibrium is reached and the rate of extraction is low, preferably zero. Another important aspect of the present invention is to avoid contamination. The preparation of the polymer gel is preferably done in a biohazard chamber with a filtered air flow. The washing steps are preferably performed using sterile materials and the gels are stored at 4°C in sterile distilled water.
To form an hybrid device that includes both the polymer device and donor tissue cells, cells can be inoculated into the porous strucweture of the polymer hydrogel by micropunctures of the polymer network using a Hamilton seringue containing the said cell suspension. Thye introduction of cells into the said polymer hydrogel can be done either in vitro or in vivo following the adequate dime after implantation of the hydrogel into the target organ area. Cells can be isolated from human brain or muscle tissue or autopsy material EXAMPLE 2: Cell inoculation into PHPMA hydrogel in vitro.
Neurons were isolated from cerebral hemispheres of rat embry7os free of meninges and blod vessels in DMEM, and were chopped into small tissue fragments. The tissues were mechanically dissociated with a Pasteur pipette in a centrifuge tube containing DMEM. The supernatant was saved and the settled tissue fragments were further disrupted with a Pasteur pipette that had been fire polished to narrow the tip. After several cycles of cell resuspension/dissociation, the pooled supernatant was centrifuged, and the cells were concentrated to 10^ cells per 100 μl of medium. The fraction is kept on ice until used for cell entrapment. For efficient and reliable penetration of cells into the polymer hydrogel, cells were introduced into an Hamilton seringue attached to a micromanipulator device and were inoculated with mini9mal pressure damage at the desired concentration into the swollen PHPMA hydrogels under a binocular microscope and in aseptic contions. The cell-containing hydrogels are kept in a minimal volume of culture mediuδm and incubated at 37°C and 5% CO2 in a humidified atrmosphere. Once the cells have reached the appropriate degree of growth, the hybrid device can be transplanted into the brain to facilitate tissue reconstruction and repair.
The polymer mixture can be mixed with living cells, thereby combining the physical characteristics of the polymer matrix with hydrogel-type behavior (porosity, stability, guidance surfaces, permeability) and cellular biological factors (e.g., growth factors).
The introduction of the cells into a polymer matrix is achieved by a gel- entrapment process at a temperature below zero, i.e., cryopolymerization, that yields a porous matrix within which cells are immobilized and can achieve reorganization, growth and/or differentiation for subsequent transplantation. The solvent should be an isotonic solution or tissue culture medium of the type which is commonly used in cell and tissue cultures combined with a suitable ciyoprotectant (glycerol/dimethylsufoxide or glycerol or DMSO or polyvinylpyrrolidone or hydroxyethyl starch, carboxymethylcellulose). The process allows to control the final cell densities ranging from a few cells to cell densities approaching the cell density of tissue, approximately 10^ to 1010 cells/cm^. The process allows also to vary and control the matrix porosity by varying the rate of cooling and the temperature of the polymerization mixture containing cells (liquid nitrogen or cooled isopentane). The process yields a macroporous spongy structure typical of cryogel with pore size that permit diffusion of nutrients and macromolecules (e.g., growth factors) to and from the cells entrapped within the polymer gel matrix and cell migration, and a pore volume suitable for effective biomass accumulation, expansion (cell division) and organization (cell-to-cell contact) during tissue development and maturation.
EXAMPLE 3: Gel entrapment of astracytes by cryopolymerization of HPMA
Astracytes were obtained by incubation of cerebral cortices of two-day old new born rats in a solution containing 0.1% trypsin-EEDTA, 0.001% DNAse in Hepes buffered DMEM for 30 min at 37°C and mechanaical dissociation. Cells were plated onto plastic flasks at 10^ cells/ 10 ml and maintained at 37°C in DMEM with 10% iFetal Bovin Serum. After 7 day in vitro, astracytes were harvested and suspended in Hank's balanced salt solution (HBSS, pH 7.4) containing 20% glycerol, concentrated to 106 per lOOμl and kept at 6°C The entrapment procedure was carried out in a laminar flow cabinet and using sterile materials. The pre-polymerization solution consisted of 0.69 g of N-(2-hydroxypropyl)methacrylamide and 0.010 g of methylenebisacrylamide dissolved in 2.3 mL of HBSS containing 20% glycerol, and as initiators, ammonium persulfate (lOOmg/mL HBSS; 4.3 X 10_3 M) wiith N^N^N'-tetramethylene diamine diluted in HBSS (1:1 v/v HBSS; 3.3 x 10"5 M). The pH was adjusted to 7.0 with HC1 0.1N and the pre- polymerization solution was deaerated with nitrogen and precooled to 4°C prior to being used. Cells were suspended in the high-density pre-polymer mixture at a density of 10^ cells/ml and the misture was thoroughly mixed and injected using an Hamilton seringue between two pre-cooled glass plates separated by 0.75 mm with silicone rubbner sealant for a final volume of 3 mL. The mold was cooled down to -170°C in approximately 1 min by immersion into liquid nitrogen, and they were left for 3 min in liquid nitrogen prior to their transfer to a water bath cooled at -15°C The polymerization reaction was carried out for 5 h in the cooled water bath, afterwards the molds were thawed in a 37°C ice bath. After ice disintegration, the gels were removed from the mold, washed with HBSS to remove the cryoprotective agent and unreacted reaction products, and trimmed into circular discs with 0.8 mm diameter. The gel discs were incubated at 37°C and 5% CO2 m ft humidified atmosphere m DMEM supplemented with 10% FBS and 1% antibiotics (streptomicine- penicilline).
This approach for fabrication of polymer hydrogel hybrid tissues has two main advantages compared to the procedure disclosed by Woerly et al.
(1996): prevention of membrane cell damage by polymerization at low temperature, and the formation of ice crystal around the cells that result in an increased porosity and a fixed pore structure (heterogeneous hydrogel). As a result, the cells are entrapped within the polymeric matrix with a scaffold architecture for organization, large inner surface area, sufficient void spaces for cell expansion and increased permeability. In addition, the cell polymer mixture can be kept stored once frozen for subsequent polymerization as described above.
At any stage of cell development, the resulting hybrid matrix consists of a solid phase that comprises the porous matrix, the cells and the cell extracellular matrix, and a fluid phase corresponding to the cell culture medium and extracellular fluids. As will be appreciated by one skilled in the art, this process is different from the so-called process "cell encapsulation" that uses micro or macroencapsulation techniques and wherein the cells are simply enclosed within a polymer membrane having a spherical shape of variable diameter. As used herein, the terms "cell(s)" intend to include tissue fragments, cell clumps, single cells from embryonic, neonatal or adult origin, genetically modified cells, either primary cells or immortalized cells, immortalized cell lines either from existing tumor cell lines or immortalized precursor cell lines, stem or progenitor cells, growth factor-selected precursor cell lines of any tissues and organs. The process and product of this invention are suitable for preparing a wide variety of artificial tissues or organs for transplantation or of three-dimensional culture systems.
To achieve this, for example, a cell suspension in Hank's balanced salt solution (sterile HBSS, pH 7.4) containing 10% to 20% glycerol as cryoprotectant was incubated for 10 minutes at 4°C. The prepolymerization solution consisting of a polymerizable composition as described in EXAMPLE 1 is dissolved in HBSS containing 10% to 20% glycerol. The solution is filtered through a porous glass filter and deaerated in vacuo and precooled in ice. Free radical polymerization is initiated with persulfate ascorbic acid or persulfate teframethylenediamine dissolved in HBSS. The pH of the solution is adjusted to neutral with HC1 IN. The cells are suspended in the polymerization solution at a variable density, preferably 10^ cells/ml of polymerization mixture. The mixture is thoroughly mixed and loaded in a syringe and injected in ampoules or in a mold made of two glass plates separated by silicone rubber sealant of variable sizes or in ampoules. The mold or ampoules are rapidly frozen by immersion in liquid nitrogen and transferred in a water bath cooled at -10° to -30°C The cryopolymerization reaction is carried out for at least 5 hours, preferably 12 hours. After polymerization, the molds or ampoules are thawed off in a 37°C water bath and the gels are removed, washed with HBSS, and can be sized to appropriate shapes. The gels are transferred to a 5% CO2 incubator with the preferred culture medium containing antibiotics and antifungic drugs. The procedure is done in a flow cabinet and using sterile instruments. TEST 1 The biological tolerance of the polymer hydrogels of the invention was studied by implantation in the transected spinal cord and in brain lesions of rats. Samples for testing were taken up from 1 week up to 10 months after implantation. Biological tolerance was excellent. Macroscopically, the gels integrate to host tissue showing a good stability and in some cases the host organ appears intact. Microscopically, studies have shown that this polymer hydrogel formulation promotes tissue restructuring and axonal regeneration at the site of implantation in the hemi- and transected rat spinal cord and thus achieving up to 100% of tissue continuity restoration (Fig. 4). Data are summarized as follows: (i) integration of the hydrogel and restoration of the continuity of the organ; the hydrogel keeps the volume of lesion constant so that a new tissue can develop and replace the lesion by adhesion of its porous surface to the wound; (ii) smooth interface with the total available polymer surface; (iii) minimal scarring and absence of cystic cavitation in the adjacent host tissue; (iv) ingrowth of a glial-based tissue network within the polymer network reinforcing the attachment of the implant to the host; (v) ingrowth of cells of heterogeneous origin; (vi) capillary ingrowth; (vii) deposition of extracellular matrix molecules (collagen, fibronectine and lanrinin) at the surface of the polymer network as seen by irnmunohistochemistry, and (viii) axonal growth throughout the bioimplant. Infrared spectioscopy studies of explanted hydrogels shows that the infrared spectrum of the native hydrogel (non implanted) has been substituted by typical infrared features of lipid and protein compounds similar to the adjacent spinal tissue, confirming that spinal cord tissue elements are integrated to the porous network of the hydrogel. TEST 2
The cryopolymerisation procedure allowed to generate heterogeneous gels with fixed macroporous structure into which cells are immobilized. Studies using cell labeling technique, such as cell labeling or immunocytochemistry, show that the cells are uniformly distributed throughout the polymer network and at different levels within the gels, either as individual isolated cells or arranged in small clusters of a few cells. The cells which survive were positively immunostained throughout three weeks in vitro incubation with antigenic profiles of developing neural tissue cells. Hence, astracytes isolated from the neonatal brain of rats can be trapped within hydrophilic hydrogels by cryopolymerization reaction with high levels of retention and the entrapped cells can survive and normally differentiate as they do in monolayer culture conditions: after 10 days in vitro, the viability of entrapped cells is of 90% using cell labeling techniques. In addition, the cells are functional as they synthesize laminin and fibronectine within the polymer matrix as they do in monolayer cultures.
The polymer hydrogel is intended to be used mainly as a tissue expander and a tissue formation template to replace tissue defect or tissue deficit of soft organs of the body, that result from either a trauma or a surgical manipulation or a congenital malformation, by promoting the formation of a new functionally integrated tissue-to-organ. It is also intended to be used to engineer wound healing, tissue remodelling, tissue regeneration, tissue development of soft organs such as liver, pancreas, skin, muscle. It can also be used in combination with other materials for bone regeneration and repair.
Another application of the polymer hydrogel is to develop procedures to provide therapy for specific human neurological disorders, and the said polymer hydrogel can be used in two different ways according to the type of disease and the extent of the functional defect. First, it can be used as tissue regeneration template or as cell carrier after incorporation of a cell graft. The polymer hydrogel according to the invention is for instance intended to be used to treat damaged or congenital defect of specific areas of the brain and spinal cord in the developing stage or the adult stage (e.g., spinal cord injury). Typically, the procedure consists in removing the damaged tissue or scar tissue or any malfunction part of the neural tissue and replacing the cerebral tissue or spinal cord tissue with the polymer hydrogel described above. The polymer hydrogel according to the invention is also useful to reconstitute neuronal circuits that are associated with axonal pathways in the central nervous system in the developing stage or the adult stage. For example, the septo- hippocampala circuits that are involved in the memory function that is impaired for example in Alzheimer disease or the nigro-striatal circuits that are involved in Parkinson disease or part of the striatum in Huntington's disease, or in hormonal/reproduction dysfunctions involving the hypophyso-hypothalamus anatomical system. This is accomplished by surgically removing the defective part of the brain tissue and implanting the gel according to the invention preferably with a neural cell graft in order to induce the formation of new functional axonal circuits. In the same way, malformations that result in malfunction of the spinal cord circuits (e.g., spina bifida) can be treated by removing the abnormally formed part of the organ and replacing the defective part by the neurogel according to the invention, preferably with a neuronal cell graft. Another application of the hydrogel according to the invention is the treatment of the optic nerve and peripheral nerves by inducing in the same way axonal regrowth through the polymer hydrogel according to the invention.
It is understood that the present invention is not limited to the preferred embodiments described above and that modifications are possible without departing from the spirit and scope of the present invention.

Claims

1. A polymer hydrogel for therapeutic use, said hydrogel being a copolymer of (a) an N-substituted methacrylamide or acrylamide, (b) a cross- linking agent and (c) a copolymerizable material selected from the group consisting of a complex sugar, a sugar derivative, a tissue adhesion peptide and a polymer conjugate with antibodies against lipid derivatives, said polymer hydrogel being heterogeneous, elastically deformable and having an equilibrium water content of at least about 80%.
2. A polymer hydrogel according to claim 1, wherein (a) said N- substituted methacrylamide or acrylamide is selected from the group consisting of N-monoalkyl and N,N-dialkyl methacrylamides and acrylamides, (b) said crass-linking agent comprises acrylamide or precursors thereof, and (c) said polymerizable material is a sugar which is selected from the group consisting of glucosamine, N-acetyl glucosamine and an N-acetyl derivative of neuraminic acid.
3. A polymer hydrogel according to claim 2, wherein said alkyl contains 1 to 2 carbon atoms.
4. A polymer hydrogel according to claim 3, wherein said alkyl is a hydraxyalkyl or aminoalkyl radical.
5. A polymer hydrogel according to claim 1, wherein said equilibrium water content is at least 96%.
6. A polymer hydrogel according to claim 1, wherein said hydrogel is covalently cross-linked, substantially non-transparent and constitutes a heterogeneous material.
7. A polymer hydrogel according to claim 6, wherein said hydrogel shows a clear phase separated structure formed of polymer particles of about 1 to 10 μm thereby providing an area of relatively coarse porosity where the hydrogel is intended to interface with a host tissue and of relatively fine porosity where it is intended to interface with ingrowing tissue.
8. A polymer hydrogel according to claim 1, having a macroporous structure with a fractional porosity of at least 80 to 90%, a specific surface area of at least 100 square meter/gram, a median pore diameter of about 15 to 35 μ m, a porous volume of pores measuring at least 10 μm equal to 100% of the fractional porosity of the hydrogel, and a hyperporous character in the range between 20 to 30 μm.
9. Method for preparing a polymer hydrogel for therapeutic use, which comprises (a) dissolving a cross-linking agent in a solvent with a free radical polymerization initiator to form a solution, (b) adding an N-substituted methacrylamide or acrylamide to the solution obtained in (a) to form a mixture, (c) adding a solution of a polymerizable material comprising complex sugar, a complex sugar derivative, a tissue adhesion peptide or a polymer conjugate with antibodies against Upid derivatives to the mixture obtained in (b) under conditions effective to give said polymer gel.
10. Method according to claim 9, which comprises dissolving azobisisobutyronitrile and methylene bisacrylamide in said solvent, to form a solution, mixing said solution with N-2-(hydraxypropyl) methacrylamide, adding glucosamine or N-acetyl glucosamine or N-acetymeuraminic acid thereto and removing low molecular weight residual products and initiator traces therefrom.
11. Method according to claim 9, wherein said cross-linking agent is selected from the group consisting of acrylamide, precursors thereof and divinyl cross-linking agents.
12. Method according to claim 9, wherein said polymerization initiator is selected from the group consisting of azobisisobutyronitrile, peroxides, ascorbic acid, peroxysulfates, and substituted aza compounds, and is used in amounts ranging between 0.01 and 2% by weight with respect to the polymer hydrogel formed.
13. Method according to claim 12, wherein said solution of polymerizable material comprises a complex sugar.
14. Method according to claim 13, wherein said complex sugar is selected from the group consisting of glucosamine, N-acetyl glucosamine, N- acetyl derivatives of neuraminic acid, polysiaUc acid and galactosene.
15. Method according to claim 12, wherein said solution of polymerizable material comprises a tissue adhesion peptide.
16. Method according to claim 12, wherein said solution of polymerizable material comprises a polymer conjugate with antibodies against lipid derivatives.
17. Method according to claim 12, which is carried out at a temperature between 40° to 60°C for about 12 hours.
18. Method according to claim 9, which comprises adding living tissue cells or genetically modified cells to the product obtained in (c) and effecting polymerization of said cells with said product.
19. A copolymerized polymer hydrogel according to claim 1, wherein living tissue cells or genetically modified ceUs are polymerized therewith.
20. Method for treating damaged cerebral tissues or a spinal cord which comprises removing said damaged cerebral tissues or spinal cord in a human being or animal and replacing said damaged cerebral tissues or spinal cord with a polymer hydrogel according to claim 1.
21. A copolymer hydrogel for therapeutic use, said hydrogel being a copolymer of (a) an N-substituted methacrylamide or acrylamide, (b) a cross- linking agent, and (c) a polymerizable tissue - adhesive material.
22. Method for treating scar, damaged or functionally defective tissue in a mammal, which comprises removing said scar, damaged or functionally damaged tissue and replacing same with a polymer hydrogel according to claim 1.
23. Method according to claim 22, for reconstituting neuronal circuits that are associated with axonal pathways in the central nervous system.
24. Method according to claim 22, for the treatment of traumatic injuries of the optic nerve and peripheral nerves.
PCT/CA1997/000766 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses WO1998016266A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP97944663A EP0929323B1 (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
AT97944663T ATE284717T1 (en) 1996-10-16 1997-10-15 IMPLANTABLE ACRYLAMIDE COPOLYMER HYDROGEL FOR THERAPEUTIC APPLICATIONS
BR9706835-7A BR9706835A (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
JP51786898A JP3542810B2 (en) 1996-10-16 1997-10-15 Therapeutic implantable acrylamide copolymer hydrogel
IL12489497A IL124894A (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
CA002240721A CA2240721C (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
SK796-98A SK79698A3 (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
DE69731959T DE69731959T2 (en) 1996-10-16 1997-10-15 IMPLANTABLE ACRYLAMIDE COPOLYMER HYDROGEL FOR THERAPEUTIC APPLICATIONS
AU46126/97A AU744666B2 (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses
NZ330664A NZ330664A (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/731,484 US5863551A (en) 1996-10-16 1996-10-16 Implantable polymer hydrogel for therapeutic uses
US08/731,484 1996-10-16

Publications (1)

Publication Number Publication Date
WO1998016266A1 true WO1998016266A1 (en) 1998-04-23

Family

ID=24939700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000766 WO1998016266A1 (en) 1996-10-16 1997-10-15 Implantable acrylamide copolymer hydrogel for therapeutic uses

Country Status (18)

Country Link
US (1) US5863551A (en)
EP (1) EP0929323B1 (en)
JP (1) JP3542810B2 (en)
KR (1) KR100377520B1 (en)
CN (1) CN1211194A (en)
AT (1) ATE284717T1 (en)
AU (1) AU744666B2 (en)
BR (1) BR9706835A (en)
CA (1) CA2240721C (en)
CZ (1) CZ187698A3 (en)
DE (1) DE69731959T2 (en)
HU (1) HUP9902027A3 (en)
IL (1) IL124894A (en)
NZ (1) NZ330664A (en)
PL (1) PL327454A1 (en)
RU (1) RU2198686C2 (en)
SK (1) SK79698A3 (en)
WO (1) WO1998016266A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165193A (en) * 1998-07-06 2000-12-26 Microvention, Inc. Vascular embolization with an expansible implant
WO2004015090A2 (en) * 2002-08-09 2004-02-19 Ottawa Health Research Institute Innervated artificial tissues and uses thereof
EP1649037A2 (en) * 2003-07-25 2006-04-26 The Government of the United States of America as represented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
WO2010097524A1 (en) 2009-02-24 2010-09-02 Woerly Stephane Hybrid heterogeneous hydrogel and its therapeutic use
EP2701745A1 (en) * 2011-04-28 2014-03-05 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
WO2016011539A1 (en) * 2014-07-22 2016-01-28 Synaptive Medical (Barbados) Inc. Method of producing anatomical phantoms with constituents having variable densities
US9446107B2 (en) 2005-12-13 2016-09-20 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9821045B2 (en) 2008-02-13 2017-11-21 President And Fellows Of Harvard College Controlled delivery of TLR3 agonists in structural polymeric devices
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
WO2021185881A1 (en) * 2020-03-17 2021-09-23 Neurobiomat Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filller implant
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US11278604B2 (en) 2012-04-16 2022-03-22 President And Fellows Of Harvard College Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317657T3 (en) * 1996-09-19 2009-04-16 The Regents Of The University Of Michigan POLYMERS CONTAINING POLYSACARIDS SUCH AS ALGINATES OR MODIFIED ALGINATES.
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US20030008396A1 (en) * 1999-03-17 2003-01-09 Ku David N. Poly(vinyl alcohol) hydrogel
JP2002516140A (en) 1998-05-23 2002-06-04 フォーカル・インコーポレーテッド How to treat premature rupture of pregnancy (PROM)
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
US6117293A (en) * 1998-07-31 2000-09-12 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
CA2353642C (en) * 1998-12-04 2009-11-10 Amarpreet S. Sawhney Biocompatible crosslinked polymers
AU776009B2 (en) * 1999-04-09 2004-08-26 Regents Of The University Of Michigan, The Preparing porous hydrogel products
US6264695B1 (en) * 1999-09-30 2001-07-24 Replication Medical, Inc. Spinal nucleus implant
JP2003520209A (en) * 1999-12-16 2003-07-02 トライデント テクノロジーズ リミテッド ライアビリティ カンパニー System and method for long term delivery of a therapeutic agent containing a receptor loading dose
EP1294480A1 (en) 2000-06-27 2003-03-26 Bia Separations D.O.O. A chromatography material and a process of manufacturing that material
US8366787B2 (en) * 2000-08-04 2013-02-05 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US6620196B1 (en) 2000-08-30 2003-09-16 Sdgi Holdings, Inc. Intervertebral disc nucleus implants and methods
CA2549687A1 (en) 2000-08-30 2002-03-07 Sdgi Holdings, Inc. Intervertebral disc nucleus implants and methods
US7503936B2 (en) * 2000-08-30 2009-03-17 Warsaw Orthopedic, Inc. Methods for forming and retaining intervertebral disc implants
US20020026244A1 (en) * 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
US7204851B2 (en) * 2000-08-30 2007-04-17 Sdgi Holdings, Inc. Method and apparatus for delivering an intervertebral disc implant
US6878384B2 (en) * 2001-03-13 2005-04-12 Microvention, Inc. Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use
KR100444944B1 (en) * 2001-05-24 2004-08-18 선바이오(주) Polyethylene glycol hydrogel for bioadhesive
US7819918B2 (en) * 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
WO2003007790A2 (en) 2001-07-16 2003-01-30 Depuy Products, Inc. Hybrid biologic/synthetic porous extracellular matrix scaffolds
US8025896B2 (en) * 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
WO2003007786A2 (en) 2001-07-16 2003-01-30 Depuy Products, Inc. Porous delivery scaffold and method
US20050027307A1 (en) * 2001-07-16 2005-02-03 Schwartz Herbert Eugene Unitary surgical device and method
AU2002316696B2 (en) * 2001-07-16 2007-08-30 Depuy Products, Inc. Cartilage repair and regeneration scaffold and method
WO2003007839A2 (en) * 2001-07-16 2003-01-30 Depuy Products, Inc. Devices form naturally occurring biologically derived
EP1416888A4 (en) * 2001-07-16 2007-04-25 Depuy Products Inc Meniscus regeneration device and method
US20040047843A1 (en) * 2002-02-12 2004-03-11 Uab Research Foundation Method for spinal cord reconnection
AU2003216379A1 (en) * 2002-02-22 2003-09-09 Control Delivery Systems, Inc. Method for treating otic disorders
US20060015083A1 (en) * 2002-03-11 2006-01-19 Munro Hugh S Absorbent hydrogels
ATE357259T1 (en) * 2002-04-10 2007-04-15 Obschestvo S Ogranichennoy Otv POLYFUNCTIONAL BIOCOMPATIBLE HYDROGEL AND METHOD FOR THE PRODUCTION THEREOF
US20040166169A1 (en) * 2002-07-15 2004-08-26 Prasanna Malaviya Porous extracellular matrix scaffold and method
US7569222B2 (en) * 2002-11-18 2009-08-04 Woerly Stephane Hydrogel membrane composition and use thereof
AU2003303206A1 (en) * 2002-12-18 2004-07-14 The Regents Of The University Of California Biocompatible hydrogel bone-like composites
WO2004071336A2 (en) * 2003-02-06 2004-08-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Hydrophilic fibrous capsule resistant prosthetic device
CA2558661C (en) * 2004-02-06 2012-09-04 Georgia Tech Research Corporation Load bearing biocompatible device
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
US7569233B2 (en) * 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US20050249772A1 (en) * 2004-05-04 2005-11-10 Prasanna Malaviya Hybrid biologic-synthetic bioabsorbable scaffolds
US20050278025A1 (en) * 2004-06-10 2005-12-15 Salumedica Llc Meniscus prosthesis
US7303074B2 (en) * 2004-09-22 2007-12-04 Dombrowski Trudy M Foldable organizer device
US20070142326A1 (en) * 2004-09-30 2007-06-21 Youe-Kong Shue Treatment of a condition in a mammal with administration of aminosugar and uses thereof
US20060089719A1 (en) * 2004-10-21 2006-04-27 Trieu Hai H In situ formation of intervertebral disc implants
US7513866B2 (en) * 2004-10-29 2009-04-07 Depuy Products, Inc. Intestine processing device and associated method
US7313829B1 (en) * 2004-10-29 2008-01-01 Payload Systems, Inc. Sealing device for body suit and sealing method using hydrogels
US7354627B2 (en) * 2004-12-22 2008-04-08 Depuy Products, Inc. Method for organizing the assembly of collagen fibers and compositions formed therefrom
CN101365500B (en) * 2005-08-26 2013-01-16 新特斯有限责任公司 Hydrogel balloon prosthesis for nucleus pulposus
WO2007043973A1 (en) * 2005-10-13 2007-04-19 Dso National Laboratories Method of enhancing a fluorescent signal
BRPI0711784B8 (en) 2006-06-15 2021-06-22 Microvention Inc embolization device constructed of expandable polymer and its method of preparation
US8066750B2 (en) 2006-10-06 2011-11-29 Warsaw Orthopedic, Inc Port structures for non-rigid bone plates
US7871440B2 (en) * 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
WO2008130263A1 (en) * 2007-04-20 2008-10-30 Institut Molekulyarnoi Biologii Im V.A. Engeldardta Rossiskoi Akademii Nauk Monomer and composition for producing low-percentage hydrogel and/or hydrogel having a low cross linkage content, a hydrogel and a biochip based thereon
WO2008130068A1 (en) * 2007-04-23 2008-10-30 Modern Cell & Tissue Technologies Inc. Method for preparing a porous polymer scaffold using dry ice
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
CA2709379C (en) 2007-12-21 2016-08-16 Microvention, Inc. Hydrogel filaments for biomedical uses
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US8586086B2 (en) 2008-05-29 2013-11-19 Politecnico Di Milano Hydrogel capable of containing and conveying cells
US20120009242A1 (en) * 2008-11-03 2012-01-12 University Of Maryland, College Park Blood coagulation inducing polymer hydrogel
US10639396B2 (en) 2015-06-11 2020-05-05 Microvention, Inc. Polymers
FR2945293B1 (en) * 2009-05-11 2011-06-17 Teoxane PROCESS FOR PREPARING A RETICULATED GEL
BR112012009287A2 (en) 2009-10-26 2017-06-06 Microvention Inc embolization device made of expandable polymer
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
JP6042815B2 (en) 2010-10-08 2016-12-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11484627B2 (en) 2010-10-20 2022-11-01 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US10525169B2 (en) 2010-10-20 2020-01-07 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
WO2015095745A1 (en) 2010-10-20 2015-06-25 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US11291483B2 (en) 2010-10-20 2022-04-05 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US9320601B2 (en) 2011-10-20 2016-04-26 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants
US11058796B2 (en) 2010-10-20 2021-07-13 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US20120101593A1 (en) * 2010-10-20 2012-04-26 BIOS2 Medical, Inc. Implantable polymer for bone and vascular lesions
WO2012145431A2 (en) 2011-04-18 2012-10-26 Microvention, Inc. Embolic devices
CA3048437C (en) 2011-05-26 2022-06-21 Cartiva, Inc. Tapered joint implant and related tools
RU2521194C2 (en) * 2011-11-16 2014-06-27 Общество с ограниченной ответственностью предприятие "Репер" Matrix for cell transplantology
CN102600067B (en) * 2012-04-10 2013-08-21 武汉大学 Preparation method of glycopeptide hydrogel containing glucosamine unit and application of glycopeptide hydrogel in preparing postoperation scar inhibitor
DE102012019984A1 (en) * 2012-10-11 2014-04-17 Leibniz-Institut für Oberflächenmodifizierung e.V. Process for the preparation of porous gels with incorporated catalytically or biologically active materials and gels produced therewith and their use
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
EP2999747B1 (en) 2013-05-23 2020-08-12 206 ORTHO, Inc. Apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone
CN106456836B (en) 2014-04-29 2019-12-06 微仙美国有限公司 Polymers comprising active agents
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017526432A (en) * 2014-08-14 2017-09-14 ザ・セカント・グループ・エルエルシー Compositions, methods, and devices useful for making implantable articles
WO2016161025A1 (en) 2015-03-31 2016-10-06 Cartiva, Inc. Hydrogel implants with porous materials and methods
EP3636226A1 (en) 2015-03-31 2020-04-15 Cartiva, Inc. Carpometacarpal (cmc) implants
WO2016168363A1 (en) 2015-04-14 2016-10-20 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
RU2594427C1 (en) * 2015-06-10 2016-08-20 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Composition for formation of macroporous media used in volume culture of animal or human cells and method for production of said carrier
KR20180104635A (en) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
DE102016000458A1 (en) * 2016-01-12 2017-07-27 Friedrich-Schiller-Universität Jena Porous Glycopolymer-Functionalized Cryogels and Their Use
CN107096065B (en) * 2017-04-05 2019-11-15 浙江大学 Composite nano-fiber membrane containing polysialic acids and preparation method and application
CN108187137A (en) * 2018-02-27 2018-06-22 崔友军 A kind of preparation method of biodegradable CO2 laser weld stent
PL241064B1 (en) 2018-10-01 2022-08-01 Dolniak Blazej Method of producing for producing a viscoelastic gel supplementing the synovial fluid and a viscoelastic gel supplementing the synovial fluid
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4084802A4 (en) * 2020-01-03 2024-03-13 Repertoire Immune Medicines Inc Compositions of hydrogels and methods of use thereof
CN113599566B (en) * 2021-08-30 2022-10-25 重庆市沙坪坝区中智医谷研究院 Hydrophobic polymer hemostatic repair material, preparation method and application thereof
CN113729654B (en) * 2021-09-14 2023-03-28 华中科技大学 Skin-attached sensing system for detecting postoperative skin flap and limb blood flow state reconstruction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657553A (en) * 1984-07-24 1987-04-14 Taylor David E M Chemical substances
US4746514A (en) * 1984-09-11 1988-05-24 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Hydrogel materials formed by radiation polymerization of carbohydrates and unsaturated monomers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902295A (en) * 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657553A (en) * 1984-07-24 1987-04-14 Taylor David E M Chemical substances
US4746514A (en) * 1984-09-11 1988-05-24 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Hydrogel materials formed by radiation polymerization of carbohydrates and unsaturated monomers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLANT G W ET AL: "HYDROGELS CONTAINING PEPTIDE OR AMINOSUGAR SEQUENCES IMPLANTED INTO THE RAT BRAIN: INFLUENCE ON CELLULAR MIGRATION AND AXONAL GROWTH", EXPERIMENTAL NEUROLOGY, vol. 143, no. 2, February 1997 (1997-02-01), pages 287 - 299, XP002054523 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799047B2 (en) 1998-07-06 2010-09-21 Microvention, Inc. Vascular embolization with an expansible implant
US6500190B2 (en) 1998-07-06 2002-12-31 Microvention Vascular embolization with an expansible implant
US7029487B2 (en) 1998-07-06 2006-04-18 Microvention, Inc. Vascular embolization with an expansible implant
US9034005B2 (en) 1998-07-06 2015-05-19 Microvention, Inc. Vascular embolization with an expansible implant
US7201762B2 (en) 1998-07-06 2007-04-10 Microvention, Inc. Vascular embolization with an expansible implant
US6165193A (en) * 1998-07-06 2000-12-26 Microvention, Inc. Vascular embolization with an expansible implant
US7483558B2 (en) 1998-07-06 2009-01-27 Microvention, Inc. Vascular embolization with an expansible implant
WO2004015090A2 (en) * 2002-08-09 2004-02-19 Ottawa Health Research Institute Innervated artificial tissues and uses thereof
WO2004015090A3 (en) * 2002-08-09 2004-05-06 Ottawa Health Research Inst Innervated artificial tissues and uses thereof
EP1649037A2 (en) * 2003-07-25 2006-04-26 The Government of the United States of America as represented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
EP1649037A4 (en) * 2003-07-25 2008-04-23 Us Gov Sec Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
US10137184B2 (en) 2005-12-13 2018-11-27 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9446107B2 (en) 2005-12-13 2016-09-20 President And Fellows Of Harvard College Scaffolds for cell transplantation
US10149897B2 (en) 2005-12-13 2018-12-11 President And Fellows Of Harvard College Scaffolds for cell transplantation
US11096997B2 (en) 2005-12-13 2021-08-24 President And Fellows Of Harvard College Scaffolds for cell transplantation
US10568949B2 (en) 2008-02-13 2020-02-25 President And Fellows Of Harvard College Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US10258677B2 (en) 2008-02-13 2019-04-16 President And Fellows Of Harvard College Continuous cell programming devices
US9821045B2 (en) 2008-02-13 2017-11-21 President And Fellows Of Harvard College Controlled delivery of TLR3 agonists in structural polymeric devices
WO2010097524A1 (en) 2009-02-24 2010-09-02 Woerly Stephane Hybrid heterogeneous hydrogel and its therapeutic use
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2019201669B2 (en) * 2011-04-28 2021-04-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP3417876A1 (en) * 2011-04-28 2018-12-26 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2017204078B2 (en) * 2011-04-28 2019-04-04 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
EP2701745A4 (en) * 2011-04-28 2014-12-03 Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
EP2701745A1 (en) * 2011-04-28 2014-03-05 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US10406216B2 (en) 2011-06-03 2019-09-10 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US11278604B2 (en) 2012-04-16 2022-03-22 President And Fellows Of Harvard College Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
GB2546638B (en) * 2014-07-22 2021-02-10 Synaptive Medical Barbados Inc Method for producing anatomical phantoms with constituents having variable densities
US9947242B2 (en) 2014-07-22 2018-04-17 Synaptive Medical (Barbados) Inc. Method for producing anatomical phantoms with constituents having variable densities
GB2546638A (en) * 2014-07-22 2017-07-26 Synaptive Medical Barbados Inc Method for producing anatomical phantoms with constituents having variable densities
WO2016011539A1 (en) * 2014-07-22 2016-01-28 Synaptive Medical (Barbados) Inc. Method of producing anatomical phantoms with constituents having variable densities
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2021185881A1 (en) * 2020-03-17 2021-09-23 Neurobiomat Hybrid heterogeneous hydrogel, manufacturing method and use as an in-situ non-degradable filller implant
FR3108260A1 (en) * 2020-03-17 2021-09-24 Neurobiomat Hybrid heterogeneous hydrogel, manufacturing process and use as a non-degradable in-situ filling implant

Also Published As

Publication number Publication date
CA2240721A1 (en) 1998-04-23
PL327454A1 (en) 1998-12-07
SK79698A3 (en) 1999-01-11
DE69731959D1 (en) 2005-01-20
DE69731959T2 (en) 2006-04-13
HUP9902027A3 (en) 2001-04-28
CN1211194A (en) 1999-03-17
JP3542810B2 (en) 2004-07-14
JP2000503884A (en) 2000-04-04
EP0929323B1 (en) 2004-12-15
NZ330664A (en) 1999-10-28
CZ187698A3 (en) 1998-11-11
US5863551A (en) 1999-01-26
IL124894A (en) 2004-06-20
EP0929323A1 (en) 1999-07-21
HUP9902027A2 (en) 1999-10-28
KR100377520B1 (en) 2003-06-09
RU2198686C2 (en) 2003-02-20
CA2240721C (en) 2007-01-09
AU4612697A (en) 1998-05-11
BR9706835A (en) 1999-12-28
ATE284717T1 (en) 2005-01-15
IL124894A0 (en) 1999-01-26
KR19990072185A (en) 1999-09-27
AU744666B2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
EP0929323B1 (en) Implantable acrylamide copolymer hydrogel for therapeutic uses
US7601525B2 (en) Alginate gel scaffold having a plurality of continuous parallel microtubular copper capillaries
EP0707498B1 (en) Implantable prosthesis, kit and device for manufacturing the same
US5834029A (en) Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
Woerly et al. Intracerebral implantation of synthetic polymer/biopolymer matrix: a new perspective for brain repair
AU2004305574B2 (en) Methods and composition for soft tissue feature reconstruction
CA2121040A1 (en) Prevascularized polymeric implants for organ transplantation
Woerly et al. Cultured rat neuronal and glial cells entrapped within hydrogel polymer matrices: a potential tool for neural tissue replacement
Giannetti et al. Acrylic hydrogel implants after spinal cord lesion in the adult rat
WO2003026489A2 (en) Biopolymer and biopolymer-cell compositions for nerve tissue repair
Nilasaroya et al. Heparin‐functionalized hydrogels as growth factor‐signaling substrates
Donzelli et al. Role of extracellular matrix components in facial nerve regeneration: an experimental study
JP2003126236A (en) Porous support body prepared from biodegradable polymer for regeneration of damaged ocular tissue
Woerly et al. Synthetic polymer matrices for neural cell transplantation
RU2521194C2 (en) Matrix for cell transplantology
MXPA98004836A (en) Implantable acrylamide copolymer hydrogel for therapeutic uses
KR20030006787A (en) Chitosan bead containing tricalcium phosphate for bone substitute
Kumar et al. Macroporous Polymeric Scaffolds for Tissue Engineering Applications
Stopek et al. Opportunities for axon repair in the CNS: use of microglia and biopolymer compositions
Han Hydrogel-Electrospun Fiber Mat Composite Materials for the Neuroprosthetic Interface

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97191715.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

WWE Wipo information: entry into national phase

Ref document number: 330664

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 79698

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/004836

Country of ref document: MX

Ref document number: 1997944663

Country of ref document: EP

Ref document number: PV1998-1876

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2240721

Country of ref document: CA

Ref document number: 2240721

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1998 517868

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980704544

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: PV1998-1876

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997944663

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980704544

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019980704544

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997944663

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-1876

Country of ref document: CZ